See the difference. Experience the difference.

Discover what more JUVÉDERM™ can do for you today

Patient 1

Before treatment



After 1 syringe
JUVÉDERM™ Ultra (0.8 mL)
(2 weeks after injection)



After 2 syringes
JUVÉDERM™ Ultra (1.6 mL)
(3 weeks after injection of second syringe)

Patient 2



Before treatment



After 1 syringe
JUVÉDERM™ Ultra Plus (0.8 mL)
(2 weeks after injection)



After 2 syringes
JUVÉDERM™ Ultra Plus (1.6 mL)
(3 weeks after injection of second syringe)

The smooth, natural look and feel *that lasts*

Unretouched photographs. These photographs are not of clinical trial subjects. Individual results may vary.

In the United States, JUVÉDERM™ injectable gel is indicated for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds).
Please see important treatment considerations on reverse side.

Juvéderm™
INJECTABLE GEL

A Brief Description of Relevant Indications for Use, Contraindications, Warnings, Precautions, and Adverse Events for JUVÉDERM™ Injectable Gel

Indication: In the United States, JUVÉDERM™ injectable gel is indicated for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds).

Contraindications: JUVÉDERM™ injectable gel should not be used in patients who have severe allergies marked by a history of anaphylaxis or history or presence of multiple severe allergies. JUVÉDERM™ injectable gel should not be used in patients with a history of allergies to Gram-positive bacterial proteins.

Warnings: JUVÉDERM™ injectable gel should not be injected into blood vessels. If there is an active inflammatory process or infection at specific injection sites, treatment should be deferred until the underlying process is controlled.

Precautions: The safety of JUVÉDERM™ injectable gel for use during pregnancy, in breastfeeding females, or in patients under 18 years has not been established. The safety and effectiveness of JUVÉDERM™ injectable gel for the treatment of areas other than facial wrinkles and folds (such as lips) have not been established in controlled clinical studies. Patients who are using substances that can prolong bleeding, such as aspirin or ibuprofen, as with any injection, may experience increased bruising or bleeding at injection site. Patients should inform their physician before treatment if they are using these types of substances. As with all skin-injection procedures, there is a risk of infection. JUVÉDERM™ injectable gel should be used with caution in patients on immunosuppressive therapy, or therapy used to decrease the body's immune response, as there may be an increased risk of infection. The safety of JUVÉDERM™ injectable gel in patients with a history of excessive scarring (eg, hypertrophic scarring and keloid formations) and pigmentation disorders has not been studied. If laser treatment, chemical peel, or any other procedure based on active dermal response is considered after treatment with JUVÉDERM™ injectable gel, or if JUVÉDERM™ injectable gel is administered before the skin has healed completely after such a procedure, there is a possible risk of an inflammatory reaction at the treatment site.

Adverse events: The most commonly reported side effects are temporary injection-site redness, swelling, pain/tenderness, firmness, lumps/bumps, and bruising. Most side effects are mild or moderate in nature, and their duration is short lasting (7 days or less).

Important: For full safety information, please visit **www.juvederm.com** or call Allergan Product Support at 1-877-345-5372.

CAUTION: This device is restricted to sale by or on the order of a physician.

ALLERGAN
THE SCIENCE OF REJUVENATION™

www.juvederm.com Re-order: MDOC-02680-01 801918

Juvéderm™
INJECTABLE GEL